Clinical Trial: A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

Detailed Summary:
Sponsor: Kissei Pharmaceutical Co., Ltd.

Current Primary Outcome: SARA (Scale for the Assessment and Rating of Ataxia) [ Time Frame: 24 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: SF-8 (QOL) [ Time Frame: 24 weeks ]

Original Secondary Outcome: Same as current

Information By: Kissei Pharmaceutical Co., Ltd.

Dates:
Date Received: October 22, 2013
Date Started:
Date Completion:
Last Updated: April 15, 2016
Last Verified: April 2016